The present disclosure generally relates to a treatment apparatus and a treatment method for cervical cancer.
The number of patients with cervical cancer has an increasing tendency, and in particular, the number of young female patients in their 20s and 30s is increasing. In current treatment for cervical cancer, treatment can include removing an entire uterus from an early stage (stage I). However, for young patients, local treatment is required to conserve the uterus in order to maintain fertility. Further, in advanced stages (stage III and subsequent stages), when cancer has spread to surrounding tissues, it is difficult to remove by surgery, and thus treatment can include combining radiation therapy and chemotherapy. However, a five-year survival rate is as low as 50% in stage III and 20% in stage IV, and more effective treatment is required. As the local treatment for cancer, a treatment method using a photoreactive substance is known (for example, see United States Patent Application Publication No. 2018/0113246). In particular, a treatment method using an antibody-photosensitive substance (hydrophilic phthalocyanine) can specifically destroy target cells without destroying non-target cells such as normal cells by irradiating the antibody-photosensitive substance accumulated in a tumor with excitation light (for example, near-infrared rays), and is expected to achieve a relatively high treatment effect while minimizing side effects.
Meanwhile, in order to achieve a high treatment effect by the antibody-photosensitive substance, the antibody-photosensitive substance adsorbed to the tumor is required to be reliably irradiated with the near-infrared rays. However, the near-infrared rays have a relatively small penetration depth, and thus can be hardly emitted from a body surface to a solid cancer in a noninvasive manner. This leads to a requirement of a method for reliably irradiating a tumor in a body with light while reducing invasiveness as much as possible. In the case of cervical cancer, cancer often spreads over a wide range of a cervical canal, and a method for irradiating cancer in a wide range with light from as close as possible is required.
A treatment apparatus and a treatment method capable of effectively treating cancer in a range including at least a part of a cervix.
A treatment apparatus is disclosed, which is configured to irradiate an antibody-photosensitive substance accumulated in a tumor cell of cervical cancer with excitation light. The treatment apparatus includes: a tubular device including an elongated tubular member; and an irradiation device configured to be inserted into the tubular member. The irradiation device includes a main shaft including a distal portion and a proximal portion, a disk portion disposed on a distal side of the main shaft, a distal shaft protruding from the disk portion toward the distal side, and an irradiation unit disposed on the distal shaft and configured to emit the excitation light.
According to the treatment apparatus described above, the excitation light can be effectively emitted to the antibody-photosensitive substance accumulated in the tumor cell in a wide range including a cervix in a state in which the distal shaft is inserted into a cervical canal and the tubular member is inserted into the vicinity of a vaginal vault. Therefore, this treatment apparatus can improve a treatment effect of cancer in a range including at least a part of the cervix.
The distal shaft may be configured to emit the excitation light in a direction substantially perpendicular to an axial center of the distal shaft, and the disk portion may be configured to emit the excitation light in a substantially distal direction. Accordingly, the excitation light can be emitted to the tumor cell of the cervix from both the distal shaft and the disk portion, and thus the treatment effect can be improved.
The tubular member may include a second irradiation unit configured to emit the excitation light in a direction substantially perpendicular to an axial center direction of the tubular member and/or in a substantially distal direction. Accordingly, the excitation light can be directly emitted from the second irradiation unit provided in the tubular member to the tumor cell in the vaginal vault, which is difficult for light to reach, and thus the treatment effect can be improved.
A distal portion of the tubular member may be configured to be deformed. Accordingly, the distal portion can be deformed along the vaginal vault to be disposed in the vicinity of the vaginal vault. Therefore, the excitation light can be effectively emitted to the vicinity of the vaginal vault, which is difficult for light to reach, and the treatment effect can be improved.
The treatment apparatus may further include a fixing portion configured to fix the irradiation device to the tubular device. Accordingly, the irradiation device and the tubular member can be operated as one, and thus operability can be improved. Since the irradiation device can be maintained at an appropriate position with respect to the tubular member, the excitation light emitted from the irradiation device can be appropriately propagated to the tubular member. Therefore, the excitation light emitted from the distal shaft, the disk portion, and the tubular member can be appropriately emitted to the antibody-photosensitive substance.
The fixing portion may be a balloon that is disposed on the disk portion and configured to be inflated by inflowing a fluid in the balloon. Accordingly, by inflating the balloon inside the tubular member, the irradiation device can be rather easily and reliably fixed to the tubular member.
The fixing portion may be a balloon that is disposed on the tubular member and configured to be inflated by inflowing a fluid in the balloon. Accordingly, by inflating the balloon, the irradiation device can be rather easily and reliably fixed to the tubular member.
An axial center of the disk portion may be inclined with respect to an axial center of the main shaft, which facilitates disposing the disk portion in accordance with an inclination of a uterine vagina with respect to a vagina. Therefore, the excitation light emitted from the disk portion can be appropriately emitted to the antibody-photosensitive substance.
The treatment apparatus may further include a detection unit configured to detect fluorescence emitted by the antibody-photosensitive substance. Accordingly, a degree of destruction of the tumor cell due to emission of the excitation light can be checked by a change in the fluorescence detected by the detection unit.
A treatment method is disclosed, for example, for treating cervical cancer. The treatment method includes: intravenously administering an antibody-photosensitive substance; inserting a tubular member into a living body, for example, a vagina 12 hours to 36 hours after the intravenous administration; inserting an irradiation device into the tubular member, the irradiation device including a disk portion configured to be disposed inside the tubular member, a distal shaft protruding from the disk portion toward a distal side, and an irradiation unit configured to emit excitation light of the antibody-photosensitive substance; inserting the distal shaft into a body lumen, for example, a cervical canal while visually checking the distal shaft; and causing the irradiation unit to emit light and emitting the excitation light from the disk portion, the distal shaft, and the tubular member to a surrounding tissue.
According to the treatment method described above, the distal shaft can be inserted from an external uterine ostium into the cervical canal, and the tubular member can be inserted up to the vaginal vault or near the vaginal vault, and thus by emitting the excitation light of the antibody-photosensitive substance from the distal shaft, the disk portion, and the tubular member, the excitation light can be effectively emitted to the antibody-photosensitive substance accumulated in the tumor cell in a range including at least a part of the cervix. Therefore, this treatment method can improve the treatment effect of cancer in a range including at least a part of the cervix.
The treatment method may further include fixing a position of the irradiation device to the tubular member. Accordingly, the irradiation device and the tubular member can be operated as one, and thus the operability is improved. Since the irradiation device can be maintained at an appropriate position with respect to the tubular member, light emitted from the irradiation device can be appropriately propagated to the tubular member. Therefore, the excitation light emitted from the distal shaft, the disk portion, and the tubular member can be appropriately emitted to the antibody-photosensitive substance.
The treatment method may further include detecting fluorescence emitted by the antibody-photosensitive substance and checking an intensity of the fluorescence. Accordingly, in this treatment method, the degree of the destruction of the tumor cell due to the emission of the excitation light can be checked by detecting the fluorescence.
The checking of the intensity of the fluorescence may be performed in parallel with the emitting of the excitation light. Accordingly, in this treatment method, a tumor can be treated while detecting the fluorescence to check the degree of the destruction of the tumor cell due to the emission of the excitation light, and the treatment effect can be improved.
The checking of the intensity of the fluorescence may be performed after the emitting of the excitation light. Accordingly, in this treatment method, a result of the destruction of the tumor cell due to the emission of the excitation light can be accurately checked by detecting the fluorescence.
Another treatment method is disclosed, which includes: intravenously administering an antibody-photosensitive substance; inserting a tubular member into a living body after the intravenous administration; inserting an irradiation device into the tubular member, the irradiation device including a disk portion configured to be disposed inside the tubular member, a distal shaft protruding from the disk portion toward a distal side, and an irradiation unit configured to emit excitation light of the antibody-photosensitive substance; inserting the distal shaft into a body lumen; and causing the irradiation unit to emit light and emitting the excitation light from the disk portion, the distal shaft, and the tubular member to a surrounding tissue.
Set forth below with reference to the accompanying drawings is a detailed description of embodiments of a treatment apparatus and a treatment method for cervical cancer. Note that since embodiments described below are preferred specific examples of the present disclosure, although various technically preferable limitations are given, the scope of the present disclosure is not limited to the embodiments unless otherwise specified in the following descriptions. For convenience of explanation, dimensions in the drawings may be exaggerated and may be different from actual dimensions. In the present specification and the drawings, components having substantially the same functional configuration are designated by the same reference numerals, and a duplicate description of the components having substantially the same functional configuration will be omitted. In the present specification, a side of a device to be inserted into a body lumen is referred to as a “distal side”, and a side to be operated is referred to as a “proximal side”.
A treatment apparatus 10 according to the present embodiment is used for a treatment method for cervical cancer. The treatment apparatus 10 and the treatment method can also be used to simultaneously treat both cervical cancer and vaginal cancer. The treatment method can be used for photoimmunotherapy in which an antibody-photosensitive substance accumulated in cell membranes of target cells is irradiated with near-infrared rays, which serve as excitation light of the antibody-photosensitive substance, to destroy the target cells. The target cells are tumor cells such as cancer cells. In this treatment method, the antibody-photosensitive substance, which is obtained by binding an antibody specifically accumulated only in a specific antigen on surfaces of the tumor cells and a photosensitive substance paired with the antibody, is used as a drug. The antibody is not particularly limited, and may be, for example, panitumbab, trastuzumab, HuJ591, pertuzumab, lapatinib, palbociclib, and olaparib. The photosensitive substance can be, for example, hydrophilic phthalocyanine which is a substance that reacts with near-infrared rays having a wavelength of about 700 nm (IR700), but is not limited to hydrophilic phthalocyanine. When IR700 receives near-infrared rays having a wavelength of about 660 nm to 740 nm, a ligand of a functional group that secures water solubility is broken, causing a structural change of the IR700 from water-soluble to hydrophobic. Due to this structural change, membrane protein is extracted, holes are opened in the cell membranes, and water enters the cells, so that the cancer cells can be ruptured and destroyed. IR700 can be excited by receiving the near-infrared rays, and emits fluorescence having a wavelength different from an excitation wavelength. For example, IR700 emits fluorescence having a wavelength of 704 nm when excited by receiving near-infrared rays having a wavelength of 689 nm. A structural change of the IR700 occurs while emitting the fluorescence by a photoreaction, and IR700 also stops emitting the fluorescence when the tumor cells are destroyed and the role as a drug is finished.
The treatment apparatus 10 illustrated in
A uterus is positioned behind the vagina V, an upper portion of the uterus is connected to left and right fallopian tubes, and the external uterine ostium O at a lower portion of the uterus is connected to the vagina V. The uterus is roughly divided into a uterine corpus and the cervix U, and the cervix U includes a cervical canal CC connected to the external uterine ostium O. The vagina V includes the vaginal vault VF that expands around the external uterine ostium O. The vaginal vault VF is deeper at a posterior vaginal vault RV positioned in a posterior part of the vagina V than at an anterior vaginal vault AV positioned at an anterior part of the vagina V.
First, the treatment apparatus 10 according to the present embodiment will be described.
As illustrated in
The irradiation device 20 can include a main shaft 21 including a distal portion and a proximal portion, an elongated irradiation unit 50 that emits light, a distal shaft 24 that accommodates the irradiation unit 50, a disk portion 30 provided at the distal portion of the main shaft 21, and a first operation portion 60 connected to a proximal portion of the irradiation device 20. The treatment apparatus 10 can be used by being connected to a light output device 80.
The main shaft 21 can be a tubular body that supports the disk portion 30. The main shaft 21 accommodates a part of the elongated irradiation unit 50. The main shaft 21 can be a circular tube extending linearly, but may be bent or may not be a circular tube. The proximal portion of the main shaft 21 is fixed to the first operation portion 60. The distal portion of the main shaft 21 is fixed to a proximal portion of the disk portion 30. Scale marks 22 arranged in an axial center direction are attached to an outer peripheral surface of the main shaft 21. The scale marks 22 can be used to check a depth of insertion of the main shaft 21 into the tubular device 100 or a living body such as the vagina V.
The main shaft 21 preferably has a certain degree of rigidity such that an operator can hold the first operation portion 60 to push the main shaft 21 to a desired position. A constituent material for the main shaft 21 is not particularly limited, and can include: a metal represented by stainless steel, aluminum, titanium alloys, tin, magnesium alloys, or the like; a resin represented by polyetheretherketone (PEEK), polyamide, acrylonitrile butadiene styrene (ABS), polycarbonate, polyacetal, polyimide; or the like. A length of the main shaft 21 in the axial center direction is not particularly limited, and can be, for example, 100 mm to 400 mm.
The distal shaft 24 can be a tubular member capable of accommodating the irradiation unit 50 in the tubular member of the distal shaft 24, and is capable of transmitting light outward from the irradiation unit 50. A part of the distal shaft 24 is disposed inside the disk portion 30. The distal shaft 24 extends toward the distal side relative to the disk portion 30. The distal shaft 24 is a portion to be inserted from the external uterine ostium O into the cervical canal CC in order to emit light from an inside of the cervical canal CC to the cervix U (see
The distal shaft 24 is preferably curved to facilitate passing the distal shaft 24 through the cervical canal CC which is inclined with respect to the vagina V, but may also be formed linearly without being curved. The distal shaft 24 can be rigid, substantially rigid, or flexible. The distal shaft 24 can be formed of a transparent or translucent material capable of transmitting light having a wavelength emitted by the irradiation unit 50 accommodated in the distal shaft 24. The constituent material for the distal shaft 24 is not particularly limited, and can include: a resin represented by polymethyl methacrylate, polyethylene terephthalate, polycarbonate, polytetrafluoroethylene, or the like; glass; or the like. It is more preferable that the material for the distal shaft 24 has elasticity and has a physical property allowing the distal shaft 24 to be deformed while being bent along the cervical canal CC after being inserted into the cervical canal CC. Accordingly, it is possible to cope with individual differences in a shape of the cervical canal CC, and it is possible to reduce a burden on an inner surface of the cervical canal CC and to further improve adhesion to the inner surface of the cervical canal CC. An outer diameter of the distal shaft 24 is not particularly limited, and can be, for example, 0.5 mm to 6 mm. A length of the distal shaft 24 in the axial center direction is not particularly limited, and can be, for example, 10 mm to 50 mm.
A shape of the distal shaft 24 is not particularly limited. For example, as in a first modification illustrated in
As in a second modification illustrated in
As in a third modification illustrated in
The operator may insert the distal shaft 24 from the external uterine ostium O into the cervical canal CC in a state in which the irradiation unit 50 disposed inside the distal shaft 24 is caused to emit light. Light emitted from a portion of the distal shaft 24 inserted into the cervical canal CC is not visible to the operator. Therefore, the operator can relatively easily visually grasp the length of insertion of the distal shaft 24 into the cervical canal CC. In this case, even if the distal shaft 24 is not provided with the irregular structure 24A or the large-diameter portion 24B, the operator can visually grasp the length of insertion of the distal shaft 24 into the cervical canal CC.
As illustrated in
As illustrated in
A thickness of the disk portion 30 (a distance between the distal surface 31 and the proximal surface 32) can be substantially constant, but may be different at different portions. For example, the thickness of the disk portion 30 may decrease radially outward. Accordingly, light incident from an inner wall surface of the through hole 34 into a material for the disk portion 30 can be propagated radially outward through the material while being reflected by a surface of the material.
A constituent material for the disk portion 30 is not particularly limited as long as the constituent material has a certain degree of rigidity and can transmit light having a wavelength emitted from the irradiation unit 50, and can be, for example, silicone, polyamide, polymethyl methacrylate, polyethylene terephthalate, polycarbonate, polytetrafluoroethylene, urethane, and combinations of the constituent materials. A maximum outer diameter of the disk portion 30 is not particularly limited, and can be, for example, 10 mm to 50 mm. A length of the disk portion 30 in the axial center direction is not particularly limited, and can be, for example, 5 mm to 60 mm.
The disk portion 30 may have a structure that scatters light. Accordingly, the disk portion 30 emits light by the light received from the irradiation unit 50. Therefore, the treatment apparatus 10 can emit light to a relatively wide range through the disk portion 30 even in a range that cannot be directly irradiated with the light from the irradiation unit 50. For example, as in a fourth modification illustrated in
The disk portion 30 may be formed in various shapes. It is preferable that the disk portion 30 is appropriately selectable according to a shape of the uterine vagina UV, the vaginal vault VF, or the vagina V of the patient.
As in a seventh modification illustrated in
As in an eighth modification illustrated in
As in a ninth modification illustrated in
As in a 10th modification illustrated in
As illustrated in
As illustrated in
As a method for propagating light to the disk portion 30, the light-emitting unit 52 may not be disposed inside the main shaft 21 or the distal shaft 24. For example, as in a 12th modification illustrated in
The first operation portion 60 is a portion to be held by the operator to operate the irradiation device 20, as illustrated in
As illustrated in
The tubular proximal portion 111 can be a circular tube, and the second operation portion 120 is fixed to a proximal portion of the tubular proximal portion 111. The tubular proximal portion 111 is formed of a transparent material to ensure a visual field of the operator. Scale marks 115 arranged in the axial center direction are attached to an outer peripheral surface of the tubular proximal portion 111. The scale marks 115 can be used to check a depth of insertion of the tubular proximal portion 111 into the irradiation device 20 or a living body such as the vagina V. A constituent material for the tubular proximal portion 111 is not particularly limited as long as the constituent is transparent, and can be, for example, silicone, polyamide, polymethyl methacrylate, polyethylene terephthalate, polycarbonate, polytetrafluoroethylene, urethane, and combinations of the constituent materials listed.
The tubular distal portion 112 is a circular tube disposed on a distal side of the tubular proximal portion 111. The tubular distal portion 112 is formed of a transparent or translucent material capable of transmitting light having a wavelength emitted by the irradiation unit 50. A constituent material for the tubular distal portion 112 is not particularly limited, and can be, for example, silicone, polyamide, polymethyl methacrylate, polyethylene terephthalate, polycarbonate, polytetrafluoroethylene, urethane, and combinations of the constituent materials listed. The tubular distal portion 112 has a structure that diffuses or scatters light. Therefore, similarly to the disk portion 30, the tubular distal portion 112 may contain scatterers in at least a part of the constituent material, may have multiple irregularities formed on an inner surface or an outer surface of the tubular distal portion 112, or may have a multi-layer structure in which materials having different refractive indexes are joined by a surface on which multiple irregularities are formed. A most distal end of the tubular distal portion 112 is inclined with respect to a plane perpendicular to an axial center. Therefore, the tubular distal portion 112 is formed with a protruding portion 113 that protrudes most in the distal direction at a part of the tubular distal portion 112 in a peripheral direction. The tubular distal portion 112 can be formed with a depression portion 114 having a smallest protruding amount in the distal direction on an opposite side of the protruding portion 113 in the peripheral direction. By disposing the depression portion 114 on an anterior vaginal vault AV side near a vaginal introitus and disposing the protruding portion 113, which is on an opposite side of the depression portion 114, on a posterior vaginal vault RV side far from the vaginal introitus, the distal portion of the tubular member 110 can be brought relatively close to the entire vaginal vault VF including the anterior vaginal vault AV and the posterior vaginal vault RV. Therefore, light can be effectively emitted to a range where light is difficult to reach, including the posterior vaginal vault RV and the anterior vaginal vault AV. An outer diameter of the tubular member 110 can be, for example, 20 mm to 60 mm.
The tubular member 110 may be formed in various shapes. It is preferable that the tubular member 110 is appropriately selectable according to the shape of the uterine vagina UV, the vaginal vault VF, or the vagina V of the patient.
As in a 13th modification illustrated in
As in a 15th modification illustrated in
The second operation portion 120 is a portion to be held by the operator to operate the tubular device 100, as illustrated in
The light output device 80 can output light having any wavelength to the optical fiber 51 of the irradiation unit 50 with any intensity (power) or energy. The light output device 80 outputs near-infrared rays having a wavelength of, for example, 660 nm to 740 nm, to the optical fiber 51 such that light can be emitted at an intensity (power) of, for example, 1 mW to 5 W, and an energy of, for example, 1 Jcm-2 to 50 Jcm-2.
Next, the treatment method using the treatment apparatus 10 according to the embodiment will be described.
First, the antibody-photosensitive substance is administered intravenously. Approximately 12 hours to 36 hours after the intravenous administration, the operator inserts the tubular device 100, which is not combined with the irradiation device 20, from the vaginal introitus into the vagina V. The tubular member 110 passes through the vaginal introitus starting from the tubular distal portion 112 and is inserted into the vagina V. At this time, the second operation portion main body 121 of the tubular device 100 extends from the outer peripheral surface of the tubular member 110 at the proximal portion toward the proximal side and extends outward in the radial direction of the tubular member 110, and does not obstruct the visual field of the operator. The tubular member 110 is transparent and does not obstruct the visual field of the operator. Therefore, the operator can open the vaginal introitus by the tubular member 110 and rather easily insert the treatment apparatus 10 from the vaginal introitus into the vagina V. Therefore, this treatment method does not require a vaginal speculum. The vaginal introitus may also be opened by using a vaginal speculum.
Next, the operator inserts the irradiation device 20 into the tubular member 110 starting from a proximal side of the tubular member 110. At this time, the disk portion 30 of the irradiation device 20 is disposed inside the tubular member 110, but the first fixing portion 62 is not fixed to the second fixing portion 123. Therefore, the irradiation device 20 is movable with respect to the tubular device 100 along the axial center of the tubular member 110. Next, as illustrated in
Next, as illustrated in
Next, the operator fixes the irradiation device 20 and the tubular device 100. For this purpose, for example, the second fixing portion 123 is fixed to the first fixing portion 62. Alternatively, when the balloon 44 (the fixing portion) is disposed on the disk portion 30 as illustrated in
Next, the operator disposes the light-emitting unit 52 of the irradiation unit 50 inside the distal shaft 24. At this time, the light-emitting unit 52 is disposed at a position where light can be emitted to the disk portion 30 and the tubular distal portion 112. Thereafter, the operator operates the light output device 80 to supply near-infrared rays to the irradiation unit 50.
Accordingly, the light-emitting unit 52 inside the distal shaft 24 can effectively emit the near-infrared rays to the tumor cells C positioned in the cervix U. When the distal shaft 24 has a function of diffusing or scattering light, the distal shaft 24 diffuses the near-infrared rays and emits light. An irradiation direction of the near-infrared rays from the light-emitting unit 52 includes a direction substantially perpendicular to an axial center of the distal shaft 24. Therefore, the light-emitting unit 52 can effectively emit the near-infrared rays from the cervical canal CC to the tumor cells C positioned in the cervix U. The tubular member 110 alone can also emit near-infrared rays (see
When the near-infrared rays are emitted from the cervical canal CC, the near-infrared rays reach the antibody-photosensitive substance accumulated in the tumor cells C in the cervix U. Accordingly, a chemical change occurs in the antibody-photosensitive substance that receives the near-infrared rays, which serve as the excitation light, and then the structural change occurs in the antibody-photosensitive substance, which generates holes in the cell membranes. Accordingly, the tumor cells C irradiated with the near-infrared rays are destroyed.
Since the disk portion 30 and the tubular distal portion 112, which receive light from the light-emitting unit 52, have a function of diffusing or scattering light, the entire disk portion 30 and tubular distal portion 112 emit light. That is, a part of the near-infrared rays that reaches the disk portion 30 and the tubular distal portion 112 is transmitted through the disk portion 30 and the tubular distal portion 112. A part of the near-infrared rays that reaches the disk portion 30 and the tubular distal portion 112 is scattered or diffused by the disk portion 30 and the tubular distal portion 112, and then emitted to a wide range. Therefore, the light-emitting unit 52, the disk portion 30, and the tubular distal portion 112 can effectively emit the near-infrared rays to the tumor cells C positioned mainly at the external uterine ostium O, the uterine vagina UV, the vaginal vault VF, and the site or location that is near the vaginal vault VF and is on the vaginal introitus side relative to the vaginal vault VF of the vagina V. Multiple folds are present in a vaginal wall on the vaginal introitus side relative to the vaginal vault VF of the vagina V, and by disposing the tubular distal portion 112 near the vaginal vault VF, incident angles of the near-infrared rays to the vaginal wall become relatively small. Therefore, reflection of light can be reduced as much as possible, and the near-infrared rays can be effectively emitted to the tumor cells C.
When the near-infrared rays are emitted from an inside of the vagina V, the near-infrared rays reach the antibody-photosensitive substance accumulated in the tumor cells C mainly in the external uterine ostium O, the uterine vagina UV, the vaginal vault VF, and the site or location that is near the vaginal vault VF and is on the vaginal introitus side relative to the vaginal vault VF of the vagina V. Accordingly, the chemical change occurs in the antibody-photosensitive substance that receives the near-infrared rays, which serve as the excitation light, and then the structural change occurs in the antibody-photosensitive substance, which generates holes in the cell membranes. Accordingly, the tumor cells C irradiated with the near-infrared rays are destroyed.
The light-emitting unit 52 simultaneously emits the near-infrared rays from the inside of the cervical canal CC and the inside of the vagina V. The operator may cause the near-infrared rays to be emitted while moving the light-emitting unit 52 inside the irradiation lumen 25. Therefore, the operator can also cause the near-infrared rays to be emitted from the inside of the cervical canal CC and cause the near-infrared rays to be emitted from the inside of the vagina V separately. The operator may cause the near-infrared rays to be emitted while alternately moving the light-emitting unit 52 between the inside of the cervical canal CC and the inside of the vagina V.
As necessary, the operator can repeatedly perform treatment of emitting the near-infrared rays while moving the disk portion 30, the tubular member 110, and the irradiation unit 50 inside the vagina V and the cervical canal CC by moving the irradiation device 20 and the tubular device 100 as a whole. At this time, if the irradiation device 20 and the tubular device 100 are fixed to each other, the operation is relatively easy. Alternatively, the irradiation device 20 and the tubular device 100 may be separately operated by releasing the fixation of the irradiation device 20 and the tubular device 100. In this case, each of the irradiation device 20 and the tubular device 100 can be disposed at a desired position.
When the operator determines that the tumor cells C are sufficiently destroyed or a predetermined time passes, the operator stops emitting the near-infrared rays. Thereafter, the operator removes the second fixing portion 123 from the first fixing portion 62, and releases the fixation of the irradiation device 20 and the tubular device 100. Thereafter, the operator removes the irradiation device 20 out of the body and removes the tubular device 100 out of the body. The irradiation device 20 and the tubular device 100 may be simultaneously removed without releasing the fixation of the irradiation device 20 and the tubular device 100. Accordingly, this treatment method ends.
As described above, the treatment apparatus 10 according to the present embodiment is the treatment apparatus 10 configured to irradiate the antibody-photosensitive substance accumulated in the tumor cell C of cervical cancer with the excitation light. The treatment apparatus 10 can include: the tubular device 100 including the elongated tubular member 110; and the irradiation device 20 configured to be inserted into the tubular member 110. The irradiation device 20 includes the main shaft 21 including the distal portion and the proximal portion, the disk portion 30 disposed on a distal side of the main shaft 21, the distal shaft 24 protruding from the disk portion 30 toward the distal side, and the irradiation unit 50 disposed on the distal shaft 24 and configured to emit the excitation light.
According to the treatment apparatus 10 described above, the excitation light can be effectively emitted to the antibody-photosensitive substance accumulated in the tumor cells C in a relatively wide range including the cervix U in a state in which the distal shaft 24 is inserted into the cervical canal CC and the tubular member 110 is inserted into the vicinity of the vaginal vault VF. Therefore, this treatment apparatus 10 can improve a treatment effect of cancer in a range including at least a part of the cervix U.
The distal shaft 24 may be configured to emit the excitation light in the direction substantially perpendicular to the axial center of the distal shaft 24, and the disk portion 30 may be configured to emit the excitation light in a substantially distal direction. Accordingly, the excitation light can be emitted to the tumor cells C of the cervix U from both the distal shaft 24 and the disk portion 30, and thus the treatment effect can be improved.
The tubular member 110 may include the optical waveguide 119 (the second irradiation unit) configured to emit the excitation light in the direction substantially perpendicular to the axial center of the tubular member 110 and/or in the substantially distal direction. Accordingly, the excitation light can be emitted from both the irradiation unit 50 provided in the irradiation device 20 and the optical waveguide 119 (the second irradiation unit) provided in the tubular member 110 to the tumor cells C in the cervix U, and thus the treatment effect can be improved. Since the excitation light can be directly emitted from the optical waveguide 119 provided in the tubular member 110 to the tumor cells C in the vaginal vault VF, which is difficult for light to reach, the treatment effect can be improved.
The distal portion of the tubular member 110 may be configured to be deformed. Accordingly, the distal portion of the tubular member 110 can be deformed along the vaginal vault VF to be disposed in the vicinity of the vaginal vault VF. Therefore, the excitation light can be effectively emitted to the vicinity of the vaginal vault VF, which is difficult for light to reach, and the treatment effect can be improved.
The treatment apparatus 10 may further include the fixing portion configured to fix the irradiation device 20 to the tubular device 100. Accordingly, the irradiation device 20 and the tubular member 110 can be operated as one, and thus operability is improved. Since the irradiation device 20 can be maintained at an appropriate position with respect to the tubular member 110, the excitation light emitted from the irradiation device 20 can be appropriately propagated to the tubular member 110. Therefore, the excitation light emitted from the distal shaft 24, the disk portion 30, and the tubular member 110 can be appropriately emitted to the antibody-photosensitive substance.
The fixing portion may be the balloon 44 that is disposed on the disk portion 30 and configured to be inflated by inflowing a fluid in the balloon 44. Accordingly, by inflating the balloon 44 inside the tubular member 110, the irradiation device 20 can be rather easily and reliably fixed to the tubular member 110.
The fixing portion may be the balloon 115 that is disposed on the tubular member 110 and configured to be inflated by inflowing a fluid in the balloon 115. Accordingly, by inflating the balloon 115, the irradiation device 20 can be rather easily and reliably fixed to the tubular member 110.
An axial center of the disk portion 30 may be inclined with respect to the axial center of the main shaft 21, which facilitates disposing the disk portion 30 in accordance with an inclination of the uterine vagina UV with respect to the vagina V. Therefore, the excitation light emitted from the disk portion 30 can be appropriately emitted to the antibody-photosensitive substance.
The treatment method according to the present embodiment is a treatment method for cervical cancer. The treatment method includes: intravenously administering the antibody-photosensitive substance; inserting the tubular member 110 into the vagina V 12 to 36 hours after the intravenous administration; inserting the irradiation device 20 into the tubular member 110, the irradiation device 20 including the disk portion 30 configured to be disposed inside the tubular member 110, the distal shaft 24 protruding from the disk portion 30 toward the distal side, and the irradiation unit 50 configured to emit the excitation light of the antibody-photosensitive substance; inserting the distal shaft 24 into the cervical canal CC; and causing the irradiation unit 50 to emit light and emitting the excitation light from the disk portion 30, the distal shaft 24, and the tubular member 110 to a surrounding tissue.
According to the treatment method described above, the distal shaft 24 can be inserted from the external uterine ostium O into the cervical canal CC, and the tubular member 110 can be inserted up to the vaginal vault VF or near the vaginal vault VF, and thus by emitting the excitation light of the antibody-photosensitive substance from the distal shaft 24, the disk portion 30, and the tubular member 110, the excitation light can be effectively emitted to the antibody-photosensitive substance accumulated in the tumor cells C in a range including at least a part of the cervix U. Therefore, this treatment method can improve the treatment effect of cancer in a range including at least a part of the cervix U.
The treatment method further includes fixing a position of the irradiation device 20 to the tubular member 110. Accordingly, the irradiation device 20 and the tubular member 110 can be operated as one, and thus the operability can be improved. Since the irradiation device 20 can be maintained at an appropriate position with respect to the tubular member 110, light emitted from the irradiation device 20 can be appropriately propagated to the tubular member 110. Therefore, the excitation light emitted from the distal shaft 24, the disk portion 30, and the tubular member 110 can be appropriately emitted to the antibody-photosensitive substance.
The disclosure is not limited to the embodiments described above, and various modifications can be made by those skilled in the art within a scope of the technical idea of the disclosure.
For example, as illustrated in
When the antibody-photosensitive substance accumulated in the tumor cells C is irradiated with the near-infrared rays, the antibody-photosensitive substance causes a photoreaction to emit the fluorescence, and destroys the tumor cells C. The antibody-photosensitive substance stops emitting the fluorescence after the tumor cells C are destroyed. Therefore, a degree of destruction of the tumor cells C due to emission of the excitation light can be checked by measuring a change in an intensity of the detected fluorescence by the optical sensor 92. Therefore, a progress state of the photoreaction for destroying the tumor cells C can be checked.
The detection unit 90 may be a device different from the treatment apparatus 10 including the irradiation unit 50 described above as long as the detection unit 90 can detect the fluorescence emitted by the antibody-photosensitive substance excited by receiving the near-infrared rays. The detection unit 90 may be inserted into the vagina V, a uterus, a rectum, a bladder, a urethra, an abdominal cavity, a blood vessel, a ureter, or the like to detect fluorescence. The detection of the fluorescence by the detection unit 90 may be performed in parallel with emission of the near-infrared rays by the treatment apparatus 10, or may be performed after the emission of the near-infrared rays by the treatment apparatus 10 is ended. The detection unit 90 may be inserted into the vagina V or the cervical canal CC after the treatment apparatus 10 is drawn out of the cervical canal CC and the vagina V. The detection unit 90 may detect fluorescence from a body surface outside a body in parallel with the emission of the near-infrared rays by the treatment apparatus 10 or after the emission of the near-infrared rays.
When the operator inserts the treatment apparatus 10 into the vagina V or the cervical canal CC, the detection unit 90 may be used to check a length of insertion of the treatment apparatus 10. For example, a position of the treatment apparatus 10 can be checked based on an image obtained from the CMOS image sensor or a change in the intensity or color of light obtained from the optical waveguide 91 such as an optical fiber.
In the tubular member 110, a reflection member may be interposed between the tubular proximal portion 111 and the tubular distal portion 112. The reflection member helps prevent the light emitted from the tubular distal portion 112 from being propagated to the tubular proximal portion 111, and thus the emission at the tubular distal portion 112 can be more efficiently performed.
In the tubular member 110, the constituent material for the tubular proximal portion 111 may not be a transparent material, and may be, for example, a metal material represented by stainless steel or the like. As a result, a wall thickness can be reduced while maintaining a rigidity of the tubular member 110, and the operability can be further improved.
The detailed description above describes embodiments of a treatment apparatus and a treatment method for cervical cancer. These disclosed embodiments represent examples of the treatment apparatus and the treatment method for cervical cancer disclosed here. The invention is not limited, however, to the precise embodiments and variations described. Various changes, modifications and equivalents can be effected by one skilled in the art without departing from the spirit and scope of the invention as defined in the accompanying claims. It is expressly intended that all such changes, modifications and equivalents which fall within the scope of the claims are embraced by the claims.
Number | Date | Country | Kind |
---|---|---|---|
2020-060402 | Mar 2020 | JP | national |
This application is a continuation of International Application No. PCT/JP2021/009429 filed on Mar. 10, 2021, which claims priority to Japanese Application No. 2020-060402 filed on Mar. 30, 2020, the entire content of both of which is incorporated herein by reference.
Number | Date | Country | |
---|---|---|---|
Parent | PCT/JP2021/009429 | Mar 2021 | US |
Child | 17945286 | US |